関連する実験動画
Updated: Feb 1, 2026

11:38
A Quantitative Glycomics and Proteomics Combined Purification Strategy
Published on: March 8, 2016
15.4K
直接およびプロテオーム幅の共性阻害剤の標的部位識別のための化学タンパク質戦略
Christopher M Browne1,2, Baishan Jiang1,2, Scott B Ficarro1,2,3
1Department of Cancer Biology , Dana-Farber Cancer Institute , Boston , Massachusetts 02215 , United States.
Journal of the American Chemical Society
|December 7, 2018
まとめ
新しい化学プロテオミクスの方法CITE-IDは タンパク質の共性薬物結合部位を正確にマッピングします このアプローチにより,未十分に研究されたPKN3キナーゼを含む新薬開発標的が特定され,新しい選択性阻害剤が開発されました.
科学分野:
- プロテオミクス
- 化学生物学
- 薬物の発見
背景:
- コバレンスの薬は治療上の利点があるが,標的外システイン改変による毒性のリスクに直面する.
- 現在の方法では,タンパク質に結合する共振性阻害剤の直接的アミノ酸レベルの定量化が欠けている.
研究 の 目的:
- コヴァレンスの薬物相互作用の正確なマッピングのための新しい化学プロテオミックアプローチ,CITE-IDを開発する.
- 結合抑制剤のプロテオーム全体の選択性を特徴付け,新しい薬物の標的を特定する.
主な方法:
- CITe-Idの開発,コバルント阻害剤を濃縮剤として使用する化学タンパク質プラットフォーム.
- プロテオーム全体での用量依存システイン-チオール変異の定量分析.
- CITe-Idの適用は,不可逆的なCDK阻害体THZ1を研究する.
主要な成果:
- CITe- Idは,コバルント阻害剤による用量依存的なシステイン変化の直接的定量化を可能にしました.
- THZ1の分析は,PKN3 (C840) に新しいシステインを含む予期せぬキナーゼ標的を明らかにした.
- これは,PKN3の選択的共性阻害剤であるJZ128の開発と,その基質の特定につながった.
結論:
- CITe-Idは,共性阻害剤の選択性を特徴づけ,新しい薬効性システインを特定するための強力なツールです.
- この方法は,構造に基づく薬剤設計を促し,標的型共性療法の開発を加速します.
- この研究は,PKN3の生物学と薬物標的としての可能性に関する新しい洞察を提供します.
関連する概念動画
Covalent Bonds
162.2K
Overview
162.2K
Covalent Bonds
10.9K
Overview
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
10.9K
Network Covalent Solids
16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Antihypertensive Drugs: Direct Renin Inhibitors
1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Covalent Bonding and Lewis Structures
61.3K
Compared to ionic bonds, which results from the transfer of electrons between metallic and nonmetallic atoms, covalent bonds result from the mutual attraction of atoms for a “shared” pair of electrons.
61.3K
Covalently Linked Protein Regulators
9.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.6K

